Antifungal combination treatment: a future perspective

被引：25

作者：

Fohrer, Cecile ^{[1
]}

Fornecker, Luc ^{[1
]}

Nivoix, Yasmine ^{[1
]}

Cornila, Corina ^{[1
]}

Marinescu, Cristina ^{[1
]}

Herbrecht, Raoul ^{[1
]}

机构：

[1] Hop Hautepierre, Dept Hematol & Oncol, F-67098 Strasbourg, France

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2006年 / 27卷

关键词：

invasive fungal infections; antifungal therapy; combination treatment; aspergillosis; caspofungin; amphotericin B lipid complex;

D O I：

10.1016/j.ijantimicag.2006.03.016

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The use of antifungal combination therapy is a new clinical approach for combating fungal infections. Although few conclusive clinical studies have been performed to date, data exist that strongly suggest that combination therapy would benefit specific patient subgroups (e.g. stem-cell transplant recipients). This paper examines the evidence available from in vitro, experimental, and clinical studies, and seeks to discover viable clinical strategies for this promising new therapeutic approach. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：S25 / S30

页数：6

共 43 条

[1] Refractory aspergillus pneumonia in patients with acute leukemia - Successful therapy with combination caspofungin and liposomal amphotericin [J].

Aliff, TB ;

Maslak, PG ;

Jurcic, JG ;

Heaney, ML ;

Cathcart, KN ;

Sepkowitz, KA ;

Weiss, MA .

CANCER, 2003, 97 (04) :1025-1032

[2] In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. [J].

Arikan, S ;

Lozano-Chiu, M ;

Paetznick, V ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :245-247

[3] In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents [J].

Dannaoui, E ;

Afeltra, J ;

Meis, JFGM ;

Verweij, PE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2708-2711

[4] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

[5]

DOUGLAS CM, 2004, P 41 INT C ANT AG CH

[6]

DOWELL J, 2004, P 14 EUR C CLIN MICR

[7]

DOWELL J, 2004, P 14 EUR CLIN MICR I

[8] International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [J].

Edwards, JE ;

Bodey, GP ;

Bowden, RA ;

Buchner, T ;

dePauw, BE ;

Filler, SG ;

Ghannoum, MA ;

Glauser, M ;

Herbrecht, R ;

Kauffman, CA ;

Kohno, S ;

Martino, P ;

Meunier, F ;

Mori, T ;

Pfaller, MA ;

Rex, JH ;

Rogers, TR ;

Rubin, RH ;

Solomkin, J ;

Viscoli, C ;

Walsh, TJ ;

White, M .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :43-59

[9] In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans:: Effect of concentration and exposure time [J].

Ernst, EJ ;

Klepser, ME ;

Pfaller, MA .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 32 (03) :205-210

[10] Safety and tolerability of combination anidulafungin (ANID) and liposomal amphotericn B (LAmB) for the treatment of invasive aspergillosis (IA) [J].

Herbrecht, R ;

Graham, D ;

Schuster, M ;

Henkel, T ;

Krause, D ;

Schranz, J ;

Garbino, J ;

Caillot, D ;

Reinhardt, J ;

Maertens, J .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) :91-91

← 1 2 3 4 5 →